cyrilzakka/clinical-trials huggingface dataset:
Institutional Audit of the Use of Intravenous Acetaminophen in Infants Undergoing Pyloromyotomy

This is a retrospective chart review. The objective of the current study is to determine the analgesic efficacy and side effect profile of intravenous acetaminophen when administered to infants undergoing pyloromyotomy. In addition, recovery characteristics of infants who were administered intravenous acetaminophen will be compared to infants who did not receive intravenous acetaminophen to determine if there were any appreciable differences with regard to postoperative discomfort, PACU time, time to oral feeds and hospital discharge.


Eligibility Criteria:
Inclusion Criteria:

* patients who presented for pyloromyotomy

Exclusion Criteria:

* none
Navigation Services to Avoid Rehospitalization (NavSTAR)

This study will examine the clinical effectiveness and health economic profile of services to link hospital patients with substance use disorders to addiction treatment, promote their medical stabilization, and reduce hospital re-admissions.

In recent years, the problem of rehospitalization has come under intense focus as a major contributor to preventable morbidity and escalating healthcare costs. Substance use disorders are strongly associated with poor health outcomes and highly inefficient use of healthcare services, including repeat hospitalizations. Interventions that increase adherence to recommendations for outpatient medical care and substance abuse treatment could potentially help recently-hospitalized individuals with substance use disorders to avoid unnecessary rehospitalization, associated morbidity, and medical expenses. The current study is a randomized controlled trial comparing the effectiveness of Navigation Services to Avoid Rehospitalization (NavSTAR) vs. Treatment-as-Usual (TAU) for hospital patients with co-occurring medical problems and substance use disorders. Applying Andersen's theoretical model of health service utilization, NavSTAR will employ the promising strategies of Patient Navigation and motivational interventions to facilitate engagement in outpatient medical and substance abuse treatment, thereby lowering the likelihood of rehospitalization. Patient Navigators embedded within the substance abuse consultation liaison service at a large urban hospital will deliver patient-centered, proactive navigation and motivational services initiated during the hospital stay and continued for 3 months post-discharge. Participants randomized to TAU will receive usual care from the hospital and the substance abuse consultation liaison service, which includes referral to substance abuse treatment but no continued contact post-hospital discharge. Participants will be assessed at study entry and again at 3-, 6-, and 12-months follow-up on various measures of healthcare utilization, substance use, and functioning. The primary outcome of interest is time-to-rehospitalization through 12 months. In addition, a range of secondary outcomes spanning the medical and substance abuse service areas will be assessed. The study will include an economic evaluation of the cost, incremental cost-effectiveness, and cost-benefits of NavSTAR from the service provider perspective.

Eligibility Criteria:
Inclusion Criteria:

1. adult (ages 18 and older) hospital patients;
2. current DSM-5 SUD (not in remission) for alcohol, cocaine, or opioids
3. willing and able to provide informed consent.

Exclusion Criteria:

1. current enrollment in SUD treatment;
2. primary residence outside of Baltimore City;
3. pregnant;
4. terminal medical condition (e.g., planned discharge to hospice);
5. hospitalized for a suicide attempt.
Neurological and Psychological Effects of Combat-Related Stress

The purpose of this study is to determine what is the neurological and cognitive impact of combat exposure and prolonged stress, in the form of service in the Israeli Defense Forces.

Attention biases in threat processing have been assigned a prominent role in the etiology and maintenance of anxiety disorders. This study aimed to characterize the mental resilience of combat soldiers, and explore the neuro-cognitive impact of prolonged stress, using eye-tracking, MRI and fMRI measurements. Participants will be assessed using questionnaires, cognitive tasks and magnetic imaging at 5 timepoints over the span of 4 years. Outcome measures will be depression, anxiety and post-traumatic scores, as well as dwell time on threat in eye-tracking paradigms tested in previous studies, and blood oxygen level-dependent (BOLD) signals in magnetic resonance imaging (MRI) measurements.

Eligibility Criteria:
Inclusion Criteria:

* Soldiers in the paratroopers brigade or students in Tel-Aviv University;
* A signed consent form;
* Hebrew native speakers.

Exclusion Criteria:

* A diagnosis of a neurological disorder (i.e., epilepsy, brain injury);
* Drug or alcohol abuse;
* Cannot undergo an MRI scan, due to metal implants or other metallic foreign bodies, claustrophobia, large tattoos or irremovable piercings;
* Require glasses with a number greater than 7;
* A diagnosis of psychotic or bipolar disorders.
The Hand Osteoarthritis Exercise Trial

The purpose of this study is to evaluate the effect of a hand exercise intervention on function and osteoarthritis symptoms in persons with hand osteoarthritis .

Hand osteoarthritis (OA) is one of the most prevalent musculoskeletal diseases in an adult population. The disease may have large influences on an individual's function, health related quality of life and participation in the society. In recently published clinical guidelines for management, non-pharmacological approaches are considered as core treatments.

Several studies have demonstrated that exercise may reduce pain and improve function in persons with knee OA, and a similar effect is suggested for hip OA. Regarding effect of exercises in hand OA, available research results are limited, and randomised controlled trials (RCT) of good quality are needed.

Eligibility Criteria:
Inclusion Criteria:

* The American College of Rheumatology (ACR) classification criteria for clinical hand osteoarthritis
* FIHOA ≥ 5 at pre-baseline
* The persons must have a telephone

Exclusion Criteria:

* Persons with cognitive dysfunction
* Persons who do not understand Norwegian language
* Persons with inflammatory rheumatic diseases (e.g. rheumatoid arthritis, ankylosing spondylitis) or cancer
* Persons that have recently experienced severe trauma
* Persons that have recently gone through OA surgery or other major surgery
Efficacy Maxinom® And Maxitrol® in Reducing The Signs And Symptoms Of Acute Bacterial Conjunctivitis

The primary objective of this study is to evaluate, through clinical parameters, the effectiveness of your medicine topic Maxinom ® (dexamethasone, neomycin and polymyxin B - Union Chemicals), comparing it to the topical medication Maxitrol ® (dexamethasone, neomycin and polymyxin B - Alcon ) by the percentage of improvement (sustained response rate) at the end of treatment, among the products studied.

1. Evaluation of isolated signs and symptoms during treatment, with a record of individual scores for each parameter and observation
2. Statistical comparison of drug safety, by recording qualitative and quantitative parameters related to adverse effects occurring during treatment.

Eligibility Criteria:
Inclusion Criteria:

* Patients who agree with all study procedures and sign, by his own free will, IC;

  * Adult patients, regardless of gender, ethnicity or social status, with good mental health;
  * Patients who present at screening visit, picture of acute bacterial conjunctivitis diagnosed clinically.

Exclusion Criteria:

* Patients with clinical diagnosis or suspicion of conjunctivitis due to any process that is not due to bacterial infection, such as infections by fungi, protozoa, viruses and allergic conjunctivitis;

  * Patients with known hypersensitivity to any component of the formulas of the study drugs;
  * Patients with a history or clinical diagnosis of other lesions that may affect the outcome, such as glaucoma, corneal ulcer or scars;
  * Concomitant use of ocular medication other than the study;
  * Pregnant or lactating women;
  * Being or having been treated for any type of conjunctivitis within 15 days and have finished treatment or less than 07 days
High Dose Vitamin D vs Standard Dose Vitamin D Study

This study is being done to look at the difference, if there is a difference between two different doses of Vitamin D and the reduction of joint/muscle pain (arthralgia)that is caused by taking anti-estrogen medications (aromatase inhibitors) by breast cancer patients. The investigators hope to learn if taking a higher dose of Vitamin D is a good way to prevent aromatase inhibitor arthralgia (AIA).

Treatments with anti-estrogen agents for hormone receptor positive breast cancer is the most efficacious of systemic therapies, with aromatase inhibitors (AI's) being considered the most active anti-estrogen therapy in early stage breast cancer. But, use of these treatments has been shown to cause musculoskeletal (joint/muscle) side effects that sometimes cause patients to discontinue the use of them. Also, Vitamin D deficiency is a well know cause of a wide array of musculoskeletal issues. There is evidence that Vitamin D supplementation may help prevent arthralgia while on AI's. Therefore, the investigators want to see if giving a higher dose of Vitamin D could decrease the incidence of AIA as compared to a standard dose of Vitamin D. The investigators believe that this could possibly result in patients continued treatment with AI therapy for hormone receptor positive breast cancer.

Eligibility Criteria:
Inclusion Criteria:

* All participants must be female and at least 21 years of age
* Signed informed consent
* Patients must have had histologically confirmed stage I-III breast carcinoma that is positive for Estrogen Receptor (ER) and/or Progesterone Receptor (PR).
* Post-menopausal
* Beginning adjuvant aromatase inhibitor therapy, with no previous use within the last 6 weeks
* Bisphosphonates are allowed at the treating investigator¡¦s discretion
* Performance status (WHO/ECOG scale) 0-2.

Exclusion Criteria:

* History of kidney stones
* Hypercalcemia at baseline, defined as any corrected calcium greater than the laboratory's normal parameters
* History of either symptomatic hypercalcemia or hyperparathyroidism, at the treating investigator's discretion
* Baseline Vitamin D level greater than 50 ng/mL
* Inability or unwillingness to comply with, or follow study procedures.
* Currently taking Phenytoin or phenobarbital -7 Currently taking cholestyramine or orlistat
* Malabsorption syndrome, such as Crohn's disease

Prohibited Therapies: Patients may not take additional Calcium and Vitamin D aside from the study medications. Patients who are on cholestyramine or orlistat will not be allowed on the trial. Also, patients who are taking phenytoin or phenobarbital are not allowed on the trial either because of interaction between Vitamin D and anti-epileptic medications.
Intervention Based on Implicit Theories of Personality: Effects on Depression and Bullying

This study evaluates the efficacy of an intervention based on the Implicit Theories of Personality (ITP) in Spanish adolescents. Half of participants received the ITP intervention, while the other half received an educational intervention.

Depression and bullying are two problems arising in childhood and adolescence, which cause severe suffering. Although there are good intervention programs for children and adolescents at risk, the results for universal interventions have generally been poor. The current project will test the efficacy of an Intervention based on the Implicit Theories of Personality (ITP). This procedure has recently been developed at US by David S. Yeager and colleagues, with extraordinary results in the reduction of depression, stress, and aggression. The project includes the following aims: (1) the evaluation of the efficacy of the ITP on depressive symptoms (Study 1) and aggressive behavior (Study 2) in Spanish adolescents; (2) to test whether the intervention changes biological and cognitive variables; (3) to identify whether development and sex moderates the effects of the intervention; and (4) to test whether temperament moderates the effect of the intervention. The study involves the evaluation of the intervention in a sample of around 900 adolescents (12-18 years), randomly allocated to experimental and control condition. It is a field experiment conducted in high schools and involves multiple measures over time (self-reports and parent reports; as well as levels of cortisol, testosterone and DHEA in saliva in a subset -50%- of the participants). In summary, the project aims to respond to the challenge of health and wellness in the population through a randomized controlled trial with multiple sources of measure and from a biopsychosocial perspective. The ITP intervention has the potential to become a universal intervention to help reduce the rates of depression and bullying.

Eligibility Criteria:
Inclusion Criteria:

* Informed consent by the adolescents and their parents.
* To be fluent in Spanish.
Dexmedetomidine Versus Dexamethasone With Levobupivacaine in Interscalene Block

The investigators compared between dexamethasone and dexmedetomidine when added to levobupivacaine in the quality and duration of ultrasound-guided interscalene block during shoulder arthroscopy.

Sixty patients were enrolled and divided into three groups 20 each, Group C received 35ml levobupivacaine+2ml normal saline under ultrasound guided interscalene block. Group H received 35ml levobupivacaine+8mg dexamethasone under ultrasound guided interscalene block. Group D received 35ml levobupivacaine+100umg dexmedetomidine+1ml normal saline. The primary outcome was the postoperative pain which was assessed by Visual analog score(VAS), the secondary outcomes were the onset and duration of sensory and motor block, the total amount of analgesic requirement, and blood cortisol level.

Eligibility Criteria:
Inclusion Criteria:

* Sixty healthy patients ASA I-II
* Aged 18-60 years
* Of both sexes
* Scheduled for shoulder arthroscopy using ultrasound interscalene block were enrolled.

Exclusion Criteria:

* Patients with a history of any allergic reactions to levobupivacaine, dexamethasone or α2 agonists
* All patients with hypertension, cardiac, hepatic, renal or pulmonary diseases, - Patients who were under treatment by α2 agonist or antagonists
* Pregnant women
* Psychiatric patients
* Patients with a previous history or clinical evidence of central or peripheral neurological disease
* Coagulopathy or anticoagulant/antiaggregant therapy
* Contralateral phrenic nerve paresis
* Patients who have an infection at the site of the block.
* Every patient who had an anatomical or vascular abnormality in the upper extremity were excluded from this study.
Trial of Chinese Prescription Shugan Decoction on Irritable Bowel Syndrome（Diarrhea Type）

The purpose of this study is to evaluate the efficacy and safety of the Chinese prescription Shugan decoction on irritable bowel syndrome（diarrhea type）.


Eligibility Criteria:
Inclusion Criteria:

* Clinical diagnosis of irritable bowel syndrome（diarrhea type）
* Male of female patients between 18-65 years old
* Written informed consent

Exclusion Criteria:

* Discrepancy of irritable bowel syndrome
* Diarrhea-type of irritable bowel syndrome combine with intestinal disease
* Combined with severe heart, gallbladder, kidney, endocrine system, hemopoietic system or nervous system disease.
* Pregnancy or breast feeding women, or unwilling to have contraception.
90% Effective Dose of Norepinephrine Infusions Under Intensive and Standard Treatment in Preeclamptic Patients

The objective of this study is to investigate the 90% effective dose of norepinephrine infusions for preventing postspinal anesthesia hypotension under intensive and standard treatment in preeclamptic patients during cesarean section

Post-spinal anesthesia hypotension is a frequent complication during spinal anesthesia for cesarean section. The incidence of post-spinal anesthesia hypotension is as high as 62.1-89.7% if prophylactic measures are not taken. The 2016 ASA guidelines for obstetric anesthesia suggest avoiding hypotension following spinal anesthesia in women and emphasize the use of vasopressors, specifically alpha-receptor agonists, as the preferred strategy to prevent and manage post-spinal anesthesia hypotension. The 2018 International Consensus in the United Kingdom and Northern Ireland recommends maintaining maternal systolic blood pressure above 90% of the baseline value following lumbar anesthesia, while avoiding dropping below 80% of the baseline value. Currently, the threshold for maintaining blood pressure above 80% of the baseline value is widely adopted as a standard; however, limited evidence supports the advantage of sustaining maternal blood pressure above 90% of the baseline value. The objective of this study is to investigate the 90% effective dose of norepinephrine infusions for preventing postspinal anesthesia hypotension under intensive and standard treatment in preeclamptic patients during cesarean section.

Eligibility Criteria:
Inclusion Criteria:

* 18-45 years
* Primipara or multipara
* Singleton pregnancy ≥32 weeks
* American Society of Anesthesiologists physical status classification I to III
* Scheduled for cesarean section under spinal anesthesia

Exclusion Criteria:

* Baseline blood pressure ≥160 mmHg
* Body height \< 150 cm
* Body weight \> 100 kg or body mass index (BMI) ≥ 40 kg/m2
* Eclampsia or chronic hypertension
* Hemoglobin \< 7g/dl
* Fetal distress, or known fetal developmental anomaly
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan

The main purpose of the study is to investigate whether tirzepatide can be effectively started before Ramadan and used per label in participants with Type 2 Diabetes during the fasting month.


Eligibility Criteria:
Inclusion Criteria:

* Have a clinical diagnosis of uncontrolled Type 2 Diabetes based on the World Health Organization classification or other locally applicable diagnostic standards, and who intend to fast during Ramadan
* Have HbA1c ≥7% within 30 days prior to screening
* Are glucagon-like peptide-1 receptor agonist (GLP-1 RA) naïve
* Have had stable body weight self-reported change ≤5 kilograms (kg) during the 90 days prior to screening
* Have body mass index ≥25 kilograms per square meter (kg/m2) at screening

Exclusion Criteria:

* Have Type 1 Diabetes or gestational diabetes
* Have a history of chronic or acute pancreatitis
* Have acute or chronic hepatitis
* Have evidence of a significant, uncontrolled endocrine abnormality
* Have a history of an active or untreated malignancy
* Have New York Heart Association Functional Classification IV congestive heart failure
* Have been treated with insulin within two weeks prior to screening
Promoting Immune Health by Intermittent Fasting: a Pilot Study

The goal is to study the direct effects of long-term intermittent fasting on immune cell populations in the blood, combined with analyses of systemic metabolic fitness and inflammatory activation of leukocytes.

the investigators aim to investigate the direct effects of intermittent fasting on the molecular characteristics of monocytes and their related health benefits. In addition,the investigators want to assess the post-prandial inflammation and the potential protective role of IF on post-prandial monocyte activation and its related health benefits. This pilot study may better understand the molecular mechanisms behind IF, which could further personalize lifestyle guidance and identify novel anti-inflammatory processes that control immune responses and inflammation.

Eligibility Criteria:
Inclusion Criteria metsyn:

* BMI 30 to 43 kg/m2
* HOMA-IR index larger/same as 2.5
* And At least 3 out of 5 NCEP (National Cholesterol Education Program) metabolic syndrome criteria:
* Fasting plasma glucose ≥ 6.1 mmol/l,
* Triglycerides≥1.7mmol/l,
* Waist-circumference\>102cm,
* HDL-cholesterol\<1.04mmol/l,
* Bloodpressure≥130/85mmHg).

Inclusion healthy volunteers

* Body mass index (BMI) 18 to 25 kg/m2,
* Waist circumference between 79 cm and 94 cm and
* HOMA-IR index: ≤ 2.0 (measured as fasting insulin (pmol/L) x fasting glucose (mmol/L)) / 135)

Exclusion criteria; (all)

* Excessive weight loss of \>10% in the last months;
* Use of any medication, including proton pomp inhibitors and antibiotics in the past three months;
* Cholecystectomy;
* Untreated GI disease/abnormal bowel habits;
* Plasma aspartate aminotransferase and alanine aminotransferase are 2.5 times or more the upper limit of the normal range;
* A history of cardiovascular event (MI or pacemaker implantation);
* A history of heavy alcohol use (\>12 to 15 g of alcohol per day, or \>12 oz of beer, 5 oz of wine, or 1.5 oz of distilled spirits);
* A dependency on alcohol or unable to pause the consumption of alcohol during the study period.
* An (expected) prolonged compromised immunity (due to recent cytotoxic chemotherapy or HIV infection with a CD4 count \< 240);
* Unmotivated or not able to adhere to a specific diet;
* History of eating disorder;
* Night workers or people with deviant day/night rhythm;
* Pregnant, trying to get pregnant or breast feeding at inclusion;
* Irregular menstrual cycle;
* Hormonal replacement therapy (other than oral contraceptives).